L-kynurenine: Metabolism and mechanism of neuroprotection

Future Neurology

Volumn 3, Issue 2, 2008, Pages 169-188

  Robotka, Hermina ^a,b   Toldi, József ^a   Vécsei, László ^a  

^a UNIVERSITY OF SZEGED   (Hungary)

^b Department of Neurology ^*  (Hungary)

Author keywords

Kynurenic acid; Kynurenine metabolism; L kynurenine; Neurodegenerative disorders; Neuroprotection

Indexed keywords

(3,4 DIMETHOXYCINNAMOYL)ANTHRANILIC ACID; 2 AMINO 4(3' HYDROXYPHENYL) 4 HYDROXYBUTANOIC ACID; 3 HYDROXYDESAMINOKYNURENINE; 3 METHOXYDESAMINOKYNURENINE; 3,4 DIMETHOXY N [4 (3 NITROPHENYL) 2 THIAZOLYL]BENZENESULFONAMIDE; 3,4 DIMETHOXY[4 (NITROPHENYL)THIAZOL 2YL]BENZENESULFONAMIDE; 4,6 DIBROMO 3 HYDROXYANTHRANILIC ACID; AMPA RECEPTOR ANTAGONIST; ENZYME INHIBITOR; FCE 28833A; GLUCOSAMINE KYNURENIC ACID; GLYCERYL TRINITRATE; KYNURENIC ACID; KYNURENIC ACID DERIVATIVE; KYNURENINE; KYNURENINE 3 MONOOXYGENASE; LEVODOPA; N (4 PHENYLTHIAZOL 2 YL)BENZENESULFONAMIDE DERIVATIVE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NCR 631; NITRIC OXIDE; PNU 156561; PROBENECID; QUINOLINIC ACID; UNCLASSIFIED DRUG; UPF 648;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANGINA PECTORIS; BRAIN ISCHEMIA; CEREBROSPINAL FLUID LEVEL; CEREBROVASCULAR ACCIDENT; CORPUS STRIATUM; DEMYELINATION; DOPAMINERGIC NERVE CELL; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; DRUG RECEPTOR BINDING; DYSKINESIA; ENZYME ACTIVITY; ENZYME INHIBITION; EXCITOTOXICITY; HUMAN; HUNTINGTON CHOREA; LIPID PEROXIDATION; MIGRAINE; MULTIPLE SCLEROSIS; NERVE CELL NECROSIS; NERVE DEGENERATION; NEUROPATHOLOGY; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; SEIZURE; STRUCTURE ACTIVITY RELATION; TRAUMATIC BRAIN INJURY; TRIGEMINAL NUCLEUS; VENTRAL TEGMENTUM;

EID: 40749131240     PISSN: 14796708     EISSN: None     Source Type: Journal    
DOI: 10.2217/14796708.3.2.169     Document Type: Review

References (214)

1. Minatogawa Y, Noguchi T, Kido R: Kynurenine pyruvate transaminase in rat brain. J. Neurochem. 23, 271-212 (1974).
2. Wolf H: Studies on tryptophan metabolism in man. Scan. J. Clin. Lab. Invest. 136S, 1-186 (1974).
3. Moroni F: Tryptophan metabolism and brain function: focus on kynurenine and other indole metabolites. Eur. J. Pharmacol. 375, 87-100 (1999).
4. Ruddick JP, Evans AK, Nutt DJ, Lightman SL, Rook GA, Lowry CA: Tryptophan metabolism in the central nervous system: medical implications. Expert Rev. Mol. Med. 8, 1-27 (2006).
5. Niles IP: Melatonin interaction with the benzodiazepine-GABA receptor complex in the CNS. In: Kynurenine and Serotonin Pathways: Progress in Tryptophan Research. Schwarcz R, Young SN, Brown RR (Eds). Plenum, NY, USA (1991).
6. Stone TW: Neuropharmacology of quinolinic and kynurenic acids. Pharmacol. Rev. 45, 309-379 (1993).
7. Hilmas C, Pereira EF, Alkondon M, Rassoulpour A, Schwarcz R, Albuquerque EX: The brain metabolite kynurenic acid inhibits α7 nicotinic receptor activity and increases non-α7 nicotinic receptor expression: physiopathological implications. J. Neurosci. 21, 7463-7473 (2001).
8. Alkondon M, Pereira EF, Yu P et al.: Targeted deletion of the kynurenine aminotransferase II gene reveals a critical role of endogenous kynurenic acid in the regulation of synaptic transmission via α7 nicotinic receptors in the hippocampus. J. Neurosci. 24, 4635-4648 (2004).
9. Ball HJ, Sanchez-Perez A, Weiser S et al.: Characterization of an indoleamine 2,3-dioxygenase-like protein found in humans and mice. Gene 396, 203-213 (2007).
10. Miller CL, Llenos IC, Dulay JR, Barillo MM, Yolken RH, Weis S: Expression of the kynurenine pathway enzyme tryptophan 2,3-dioxygenase is increased in the frontal cortex of individuals with schizophrenia. Neurobiol. Dis. 15, 618-629 (2004).
11. Miller CL, Llenos IC, Dulay JR, Weis S: Upregulation of the initiating step of the kynurenine pathway in postmortem anterior cingulate cortex from individuals with schizophrenia and bipolar disorder. Brain Res. 1073-1074, 25-37 (2006).
12. Yoshida R, Imanishi J, Oku T, Kishida T, Hayaishi O: Induction of pulmonary indoleamine 2,3-dioxygenase by interferon. Proc. Natl Acad. Sci. U S A 78, 129-132 (1981).
13. Taylor MW, Feng GS: Relationship between interferon-γ, indoleamine 2,3-dioxygenase, and tryptophan catabolism. FASEB J. 5, 2516-2522 (1991).
14. Hwu P, Du MX, Lapointe R, Do M, Taylor MW, Young HA: Indoleamine 2,3-dioxygenase production by human dendritic cells results in the inhibition of T cell proliferation. J. Immunol. 164, 3596-3599 (2000).
15. Guillemin GJ, Cullen KM, Lim CK et al.: Characterization of the kynurenine pathway in human neurons. J. Neurosci. 27, 12884-12892 (2007).
16. Schrocksnadel K, Wirleitner B, Winkler C, Fuchs D: Monitoring tryptophan metabolism in chronic immune activation. Clin. Chim. Acta 364, 82-90 (2006).
17. Fukui S, Schwarcz R, Rapoport SI, Takada Y, Smith QR: Blood-brain barrier transport of kynurenines: implications for brain synthesis and metabolism. J. Neurochem. 56, 2007-2017 (1991).
18. Cooper AJ: The role of glutamine transaminase K (GTK) in sulfur and α-keto acid metabolism in the brain, and in the possible bioactivation of neurotoxicants. Neurochem. Int. 44, 557-577 (2004).
19. Schwarcz R: The kynurenine pathway of tryptophan degradation as a drug target. Curr. Opin. Pharmacol. 4, 12-17 (2004).
20. Perry SJ, Schofield MA, MacFarlane M et al.: Isolation and expression of a cDNA coding for rat kidney cytosolic cysteine conjugate β-lyase. Mol. Pharmacol. 43, 660-665 (1993).
21. Perry S, Harries H, Scholfield C et al.: Molecular cloning and expression of a cDNA for human kidney cysteine conjugate β-lyase. FEBS Lett. 360, 277-280 (1995).
22. Carninci P, Hayashizaki Y: High-efficiency full-length cDNA cloning. Methods Enzymol. 303, 19-44 (1999).
23. Plant N, Kitchen I, Goldfarb PS, Gibson GG: Developmental modulation of cysteine conjugate β-lyase/glutamine transaminase K/kynurenine aminotransferase mRNA in rat brain. Eur. J. Drug Metab. Pharmacokinet. 22, 335-339 (1997).
24. Ceresoli-Borroni G, Schwarcz R: Perinatal kynurenine pathway metabolism in the normal and asphyctic rat brain. Amino Acids 19, 311-323 (2000).
25. Guidetti P, Okuno E, Schwarcz R: Characterization of rat brain kynurenine aminotransferases I and II. J. Neurosci Res. 50, 457-465 (1997).
26. Han Q, Li J, Li J: pH dependence, substrate specificity and inhibition of human kynurenine aminotransferase I. Eur. J. Biochem. 271, 4804-4814 (2004).
27. Buchli R, Alberati-Giani D, Malherbe P, Kohler C, Broger C, Cesura AM: Cloning and functional expression of a soluble form of kynurenine/ α-aminoadipate aminotransferase from rat kidney. J. Biol. Chem. 270, 29330-29335 (1995).
28. Yu P, Mosbrook DM, Tagle DA: Genomic organization and expression analysis of mouse kynurenine aminotransferase II, a possible factor in the pathophysiology of Huntington's disease. Mamm. Genome 10, 845-852 (1999).
29. Goh DL, Patel A, Thomas GH et al.: Characterization of the human gene encoding α-aminoadipate aminotransferase (AADAT). Mol. Genet. Metab. 76, 172-180 (2002).
30. Du F, Schmidt W, Okuno E, Kido R, Kohler C, Schwarcz R: Localization of kynurenine aminotransferase immunoreactivity in the rat hippocampus. J. Comp. Neurol. 321, 477-487 (1992).
31. Guillemin GJ, Kerr SJ, Smythe GA et al.: Kynurenine pathway metabolism in human astrocytes: a paradox for neuronal protection. J. Neurochem. 78, 842-853 (2001).
32. Knyihar-Csillik E, Okuno E, Vecsei L: Effects of in vivo sodium azide administration on the immunohistochemical localization of kynurenine aminotransferase in the rat brain. Neuroscience 94, 269-277 (1999).
33. Kapoor R, Okuno E, Kido R, Kapoor V: Immuno-localization of kynurenine aminotransferase (KAT) in the rat medulla and spinal cord. Neuroreport 8, 3619-3623 (1997).
34. Yu P, Li Z, Zhang L, Tagle DA, Cai T: Characterization of kynurenine aminotransferase III, a novel member of a phylogenetically conserved KAT family. Gene 365, 111-118 (2006).
35. Guidetti P, Amori L, Sapko MT, Okuno E, Schwarcz R. Mitochondrial asparate aminotransferase: a third kynurenate-producing enzyme in the mammalian brain. J. Neurochem. 102, 103-111(2007).
36. 2O during hydroxylation of L-[3,5-3H]kynurenine. Anal. Biochem. 205, 257-262 (1992).
37. Vazquez S, Aquilina JA, Jamie JF, Shed MM, Truscott RJ: Novel protein modification by kynurenine in human lenses. J. Biol. Chem. 277, 4867-4873 (2002).
38. Guidetti P, Schwarcz R: 3-hydroxykynurenine potentiates quinolinate but not NMDA toxicity in the rat striatum. Eu.r J. Neurosci. 11, 3857-3863 (1999).
39. 3H homoquinolinate binds to a subpopulation of NMDA receptors and to a novel binding site. J. Neurochem. 71, 1464-1470 (1998).
40. de Carvalho LP, Bochet P, Rossier J: The endogenous agonist quinolinic acid and the non endogenous homoquinolinic acid discriminate between NMDAR2 receptor subunits. Neurochem. Int. 28, 445-452 (1996).
41. Guillemin GJ, Kerr SJ, Brew BJ: Involvement of quinolinic acid in AIDS dementia complex. Neurotox. Res. 7, 103-123 (2005).
42. Tavares RG, Tasca CI, Santos CE, Wajner M, Souza DO, Dutra-Filho CS: Quinolinic acid inhibits glutamate uptake into synaptic vesicles from rat brain. Neuroreport 11, 249-253 (2000).
43. Tavares RG, Tasca CI, Santos CE et al.: Quinolinic acid stimulates synaptosomal glutamate release and inhibits glutamate uptake into astrocytes. Neurochem. Int. 40, 621-627 (2002).
44. Rios C, Santamaria A: Quinolinic acid is a potent lipid peroxidant in rat brain homogenates. Neurochem. Res. 16, 1139-1143 (1991).
45. Behan WM, Stone TW: Enhanced neuronal damage by co-administration of quinolinic acid and free radicals, and protection by adenosine A2A receptor antagonists. Br. J. Pharmacol. 135, 1435-1442 (2002).
46. Schurr A, Rigor BM: Quinolinate potentiates the neurotoxicity of excitatory amino acids in hypoxic neuronal tissue in vitro. Brain Res. 617, 76-80 (1993).
47. Bordelon YM, Chesselet MF, Nelson D, Welsh F, Erecinska M: Energetic dysfunction in quinolinic acid-lesioned rat striatum. J. Neurochem. 69, 1629-1639 (1997).
48. Rodriguez-Martinez E, Camacho A, Maldonado PD et al.: Effect of quinolinic acid on endogenous antioxidants in rat corpus striatum. Brain Res. 858, 436-439 (2000).
49. Santamaria A, Galvan-Arzate S, Lisy V et al.: Quinolinic acid induces oxidative stress in rat brain synaptosomes. Neuroreport 12, 871-874 (2001).
50. Schwarcz R, Foster AC, French ED, Whetsell WO Jr, Kohler C: Excitotoxic models for neurodegenerative disorders. Life Sci. 35, 19-32 (1984).
51. Beal MF, Kowall NW, Ellison DW, Mazurek MF, Swartz KJ, Martin JB: Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid. Nature 321, 168-171 (1986).
52. Beal MF, Ferrante RJ, Swartz KJ, Kowall NW: Chronic quinolinic acid lesions in rats closely resemble Huntington's disease. J. Neurosci. 11, 1649-1659 (1991).
53. Foster AC, White RJ, Schwarcz R: Synthesis of quinolinic acid by 3-hydroxyanthranilic acid oxygenase in rat brain tissue in vitro. J. Neurochem. 47, 23-30 (1986).
54. Schwarcz R, Okuno E, White RJ, Bird ED, Whetsell WO Jr: 3-Hydroxyanthranilate orygenase activity is increased in the brains of Huntington disease victims. Proc Natl Acad. Sci. USA 85, 4079-4081 (1988).
55. Saito K, Nowak TS Jr, Markey SP, Heyes MP: Mechanism of delayed increases in kynurenine pathway metabolism in damaged brain regions following transient cerebral ischemia. J. Neurochem. 60, 180-192 (1993).
56. Du F, Williamson J, Bertram E, Lothman E, Okuno E, Schwarcz R: Kynurenine pathway enzymes in a rat model of chronic epilepsy: immunohistochemical study of activated glial cells. Neuroscience 55, 975-989 (1993).
57. Matthew CK, Van Holde KE, Ahern KG: Biochemistry. Addison-Wesley, MA, USA (2003).
58. Burkle A: Physiology and pathophysiology of poly(ADP-ribosyl)ation. Bioessays 23, 795-806 (2001).
59. Wilkinson A, Day J, Bowater R: Bacterial DNA ligases. Mol. Microbiol. 40, 1241-1248 (2001).
60. Smith JS, Boeke JD: An unusual form of transcriptional silencing in yeast ribosomal DNA. Genes Dev. 11, 241-254 (1997).
61. Rutter J, Reick M, Wu LC, McKnight SL: Regulation of clock and NPAS2 DNA binding by the redox state of NAD cofactors. Science 293, 510-514 (2001).
62. Grant RS, Naif H, Espinosa M, Kapoor V: IDO induction in IFN-γ activated astroglia: a role in improving cell viability during oxidative stress. Redox Rep. 5, 101-104 (2000).
63. Grant RS, Kapoor V: Murine glial cells regenerate NAD, after peroxide-induced depletion, using either nicotinic acid, nicotinamide, or quinolinic acid as substrates. J. Neurochem. 70, 1759-1763 (1998).
64. Heyes MP, Achim CL, Wiley CA, Major EO, Saito K, Markey SP: Human microglia convert L-tryptophan into the neurotoxin quinolinic acid. Biochem. J. 320(Pt 2), 595-597 (1996).
65. Gal EM, Sherman AD: L-kynurenine: its synthesis and possible regulatory function in brain. Neurochem. Res. 5, 223-239 (1980).
66. Guillemin GJ, Smythe G, Takikawa O, Brew BJ: Expression of indoleamine 2,3-dioxygenase and production of quinolinic acid by human microglia, astrocytes, and neurons. Glia 49, 15-23 (2005).
67. Guillemin GJ, Smith DG, Kerr SJ et al.: Characterisation of kynurenine pathway metabolism in human astrocytes and implications in neuropathogenesis. Redox Rep. 5, 108-111 (2000).
68. Moffett JR, Namboodiri MA: Tryptophan and the immune response. Immunol. Cell Biol. 81, 247-265 (2003).
69. Mellor AL, Munn D, Chandler P et al.: Tryptophan catabolism and T cell responses. Adv. Exp. Med. Biol. 527, 27-35 (2003).
70. Mellor AL, Baban B, Chandler P et al.: Cutting edge: induced indoleamine 2,3 dioxygenase expression in dendritic cell subsets suppresses T-cell clonal expansion. J. Immunol. 171, 1652-1655 (2003).
71. Mellor AL, Munn DH: IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat. Rev. Immunol. 4, 762-774 (2004).
72. Stone TW: Development and therapeutic potential of kynurenic acid and kynurenine derivatives for neuroprotection. Trends Pharmacol. Sci. 21, 149-154 (2000).
73. Stone TW: Kynurenines in the CNS: from endogenous obscurity to therapeutic importance. Prog. Neurobiol. 64, 185-218 (2001).
74. Stone TW, Mackay GM, Forrest CM, Clark CJ, Darlington LG: Tryptophan metabolites and brain disorders. Clin. Chem. Lab. Med. 41, 852-859 (2003).
75. Nemeth H, Robotka H, Toldi J, Vecsei L: Kynurenines in die central nervous system: recent developments. Cent. Nerv. Syst. Agents in Med. Chem. 7, 45-56 (2007).
76. Gardian G, Vecsei L: Huntington's disease: pathomechanism and therapeutic perspectives. J. Neural Transm. 111, 1485-1494 (2004).
77. Schwarcz, R. Whetsell WO Jr, Mangano RM: Quinolinic acid: an endogenous metabolite that produces axon-sparing lesions in rat brain. Science 219, 316-318 (1983).
78. Shear DA, Dong J, Haik-Creguer KL, Bazzett TJ, Albin RL, Dunbar GL: Chronic administration of quinolinic acid in the rat striatum causes spatial learning deficits in a radial arm water maze task. Exp. Neurol. 150, 305-311 (1998).
79. Schwarcz R, Albin RL: Ionotropic glutamate receptors as therapeutic targets. In: Huntington's Disease. Lodge D, Danysz W, Parsons CG (Eds). FP Graham Publishing Co., TN, USA 587-610 (2002).
80. Reynolds GP, Pearson SJ, Halket J, Sandler M: Brain quinolinic acid in Huntington's disease. J. Neurochem. 50, 1959-1960 (1988).
81. Heyes MP, Saito K, Crowley JS et al.: Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurological disease. Brain 115(Pt 5), 1249-1273 (1992).
82. Stoy N, Mackay GM, Forrest CM et al.: Tryptophan metabolism and oxidative stress in patients with Huntington's disease. J. Neurochem. 93, 611-623 (2005).
83. Gu M, Gash MT, Mann VM, Javoy-Agid F, Cooper JM, Schapira AH: Mitochondrial defect in Huntington's disease caudate nucleus. Ann. Neurol. 39, 385-389 (1996).
84. Browne SE, Bowling AC, MacGarvey U et al.: Oxidative damage and metabolic dysfunction in Huntington's disease: selective vulnerability of the basal ganglia. Ann. Neurol. 41, 646-653 (1997).
85. Doble A: The role of excitotoxicity in neurodegenerative disease: implications for therapy. Pharmacol. Ther. 81, 163-221 (1999).
86. Beal MF, Matson WR, Storey E et al.: Kynurenic acid concentrations are reduced in Huntington's disease cerebral cortex. J. Neurol. Sci. 108, 80-87 (1992).
87. Jauch D, Urbanska EM, Guidetti P et al.: Dysfunction of brain kynurenic acid metabolism in Huntington's disease: focus on kynurenine aminotransferases. J. Neurol. Sci. 130, 39-47 (1995).
88. Guidetti P, Luthi-Carter RE, Augood SJ, Schwarcz R: Neostriatal and cortical quinolinate levels are increased in early grade Huntington's disease. Neurobiol. Dis. 17, 455-461 (2004).
89. Rosas HD, Korosherz WJ, Chen YI et al.: Evidence for more widespread cerebral pathology in early HD: an MRI-based morphometric analysis. Neurology 60, 1615-1620 (2003).
90. Ross CA, Margolis RL: Huntington's disease. Clin. Neurosci. Res. 1, 142-152 (2001).
91. Agid Y: Parkinson's disease: pathophysiology. Lancet 337, 1321-1324 (1991).
92. Bezard E, Boraud T, Bioulac B, Gross CE: Compensatory effects of glutamatergic inputs to the substantia nigra pars compacta in experimental parkinsonism. Neuroscience 81, 399-404 (1997).
93. Schapira AH, Cooper JM, Dexter D, Jenner P, Clark JB, Marsden CD: Mitochondrial complex I deficiency in Parkinson's disease. Lancet 1, 1269 (1989).
94. Carreras MC, Franco MC, Peralta JG, Poderoso JJ: Nitric oxide, complex I, and the modulation of mitochondrial reactive species in biology and disease. Mol. Aspects Med. 25, 125-139 (2004).
95. Ogawa T, Matson WR, Beal MF et al.: Kynurenine pathway abnormalities in Parkinson's disease. Neurology 42, 1702-1706 (1992).
96. Hartai Z, Klivenyi P, Janaky T, Penke B, Dux L, Vecsei L: Kynurenine metabolism in plasma and in red blood cells in Parkinson's disease. J. Neurol. Sci. 239, 31-35 (2005).
97. Schapira AH: Present and future drug treatment for Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 76, 1472-1478 (2005).
98. Obeso JA, Olanow CW, Nutt JG: Levodopa motor complications in Parkinson's disease. Trends Neurosci. 23, S2-S7 (2000).
99. Blanchet PJ, Konitsiotis S, Whittemore ER, Zhou ZL, Woodward RM, Chase TN: Differing effects of N-methyl-D-aspartate receptor subtype selective antagonists on dyskinesias in levodopa-treated 1-methyl-4-phenyl-tetrahydropyridine monkeys. J. Pharmacol. Exp. Ther. 290, 1034-1040 (1999).
100. Hadj Tahar A, Gregoire L, Darre A. Belanger N, Meltzer L, Bedard PJ: Effect of a selective glutamate antagonist on L-dopa-induced dyskinesias in drug-naive parkinsonian monkeys. Neurobiol. Dis. 15, 171-176 (2004).
101. Papa SM, Chase TN: Levodopa-induced dyskinesias improved by a glutamate antagonist in Parkinsonian monkeys. Ann. Neurol. 39, 574-578 (1996).
102. Gregoire L, Rassoulpour A, Guidetti P et al.: Prolonged kynurenine 3-hydroxylase inhibition reduces development of levodopa-induced dyskinesias in parkinsonian monkeys. Behav. Brain Res. 186, 161-167 (2008).
103. Widner B, Leblhuber F, Walli J, Tilz GP, Demel U, Fuchs D: Tryptophan degradation and immune activation in Alzheimer's disease. J. Neural Transm. 107, 343-353 (2000).
104. Guillemin GJ, Williams, KR, Smith DG, Smythe GA, Croitoru-Lamoury J, Brew BJ: Quinolinic acid in the pathogenesis of Alzheimer's disease. Adv. Exp. Med. Biol. 527, 167-176 (2003).
105. Guillemin GJ, Brew BJ: Implications of the kynurenine pathway and quinolinic acid in Alzheimer's disease. Redox Rep. 7, 199-206 (2002).
106. Zhu X, Raina AK, Perry G, Smith MA: Alzheimer's disease: the two-hit hypothesis. Lancet Neurol. 3, 219-226 (2004).
107. Leonard BE, Myint A: Changes in the immune system in depression and dementia: causal or coincidental effects? Dialogues Clin. Neurosci. 8, 163-174 (2006).
108. Guillemin GJ, Brew BJ, Noonan CE, Takikawa O, Cullen KM: Indoleamine 2,3 dioxygenase and quinolinic acid immunoreactivity in Alzheimer's disease hippocampus. Neuropathol. Appl. Neurobiol. 31, 395-404 (2005).
109. Guillemin GJ, Smythe GA, Veas LA, Takikawa O, Brew BJ: Aβ1-42 induces production of quinolinic acid by human macrophages and microglia. Neuroreport 14, 2311-2315 (2003).
110. Moroni F, Lombardi G, Robitaille Y, Etienne P: Senile dementia and Alzheimer's disease: lack of changes of the cortical content of quinolinic acid. Neurobiol. Aging 7, 249-253 (1986).
111. Baran H, Jellinger K, Deecke L: Kynurenine metabolism in Alzheimer's disease. J. Neural Transm. 106, 165-181 (1999).
112. Sapko MT, Guidetti P, Yu P, Tagle DA, Pellicciari R, Schwarcz R: Endogenous kynurenate controls the vulnerability of striatal neurons to quinolinate: implications for Huntington's disease. Exp. Neurol. 197, 31-40 (2006).
113. Hartai Z, Juhasz A, Rimanoczy A et al.: Decreased serum and red blood cell kynurenic acid levels in Alzheimer's disease. Neurochem. Int. 50, 308-313 (2007).
114. Guillemin GJ, Brew BJ, Noonan CE, Knight TG, Cullen KM: Mass spectrometric detection of quinolinic acid in microdissected Alzheimer disease plaques. Congress Series. ICS (2007).
115. Carpenter WT Jr, Buchanan RW: Schizophrenia. N. Engl. J. Med. 330, 681-690 (1994).
116. Carlsson A, Lindqvist M: Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta. Pharmacol. Toxicol. (Copenh.) 20, 140-144 (1963).
117. Carlsson A, Waters N, Holm-Waters S, Tedroff J, Nilsson M, Carlsson ML: Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence. Annu. Rev. Pharmacol. Toxicol. 41, 237-260 (2001).
118. Javitt DC: Glutamate as a therapeutic target in psychiatric disorders. Mol. Psychiatry 9, 984-997, 979 (2004).
119. Erhardt S, Blennow K, Nordin C, Skogh E, Lindstrom LH, Engberg G: Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia. Neurosci. Lett. 313, 96-98 (2001).
120. Schwarcz R, Rassoulpour A, Wu HQ, Medoff D, Tamminga CA, Roberts RC: Increased cortical kynurenate content in schizophrenia. Biol Psychiatry 50, 521-530 (2001).
121. Erhardt S, Schwieler L, Nilsson L, Linderholm K, Engberg G: The kynurenic acid hypothesis of schizophrenia. Physiol. Behav. 92, 203-209 (2007).
122. Erhardt S, Schwieler L, Engberg G: Excitatory and inhibitory responses of dopamine neurons in the ventral tegmental area to nicotine. Synapse 43, 227-237 (2002).
123. Kepplinger B, Baran H, Kainz A, Newcombe J, Nohl H: Altered kynurenic acid levels in CSF and serum of patients with multiple sclerosis. ECTRIMS 2001 Abstracts. Mult. Scler. 7(Suppl. 1), S118 (2001).
124. Baran H, Kepplinger B, Newcombe J, Stolze K, Kainz A, Nohl H: Lowered kynurenine aminotransferase activities in CNS of MS patients. Society for Neuroscience 30th Annual Meeting. Abstract 1302 (2000).
125. Cammer W: Oligodendrocyte killing by quinolinic acid in vitro. Brain Res. 896, 157-160 (2001).
126. Rejdak K, Kocki T, Dobosz B, Turski WA, Stelmasiak Z: Decreased level of kynurenic acid in cerebrospinal fluid of relapsing-remitting multiple sclerosis patients. ECTRIMS 2001 Abstracts. Mult. Scler. 7(Suppl. 1), S118 (2001).
127. Rejdak K, Bartosik-Psujek H, Dobosz B et al.: Decreased level of kynurenic acid in cerebrospinal fluid of relapsing-onset multiple sclerosis patients. Neurosci. Lett. 331, 63-65 (2002).
128. Rejdak & Petzold A, Kocki T et al.: Astrocytic activation in relation to inflammatory markers during clinical exacerbation of relapsing-remitting multiple sclerosis. J. Neural Transm. 114, 1011-1015 (2007).
129. Hartai Z, Klivenyi P, Janaky T, Penke B, Dux L, Vecsei L: Kynurenine metabolism in multiple sclerosis. Acta Neurol. Scand. 112, 93-96 (2005).
130. Chiarugi A, Cozzi A, Ballerini C, Massacesi L, Moroni F: Kynurenine 3-mono-oxygenase activity and neurotoxic kynurenine metabolites increase in the spinal cord of rats with experimental allergic encephalomyelitis. Neuroscience 102, 687-95 (2001).
131. Guillemin GJ, Meininger V, Brew BJ: Implications for the kynurenine pathway and quinolinic acid in amyotrophic lateral sclerosis. Neurodegener. Dis. 2, 166-176 (2005).
132. Ilzecka J, Kocki T, Stelmasiak Z, Turski WA. Endogenous protectant kynurenic acid in amyotrophic lateral sclerosis. Acta Neurol. Scand. 107, 412-418 (2003).
133. Marsh N, Marsh A. A short history of nitroglycerine and nitric oxide in pharmacology and physiology. Clin. Exp. Pharmacol. Physiol. 27, 313-319 (2000).
134. Tassorelli C, Greco R, Morazzoni P, Riva A, Sandrini G, Nappi G: Parthenolide is the component of tanacetum parthenium that inhibits nitroglycerin-induced Fos activation: studies in an animal model of migraine. Cephalalgia 25, 612-621 (2005).
135. Morgan JI, Curran T: Role of ion flux in the control of c-fos expression. Nature 322, 552-555 (1986).
136. Knyihar-Csillik E, Toldi J, Mihaly A et al.: Kynurenine in combination with probenecid mitigates the stimulation-induced increase of c-fos immunoreactivity of the rat caudal trigeminal nucleus in an experimental migraine model. J. Neural Transm. 114, 417-421 (2007).
137. Knyihar-Csillik E, Tajti J, Samsam M, Sary G, Slezak S, Vecsei L: Effect of a serotonin agonist (sumatriptan) on the peptidergic innervation of the rat cerebral dura mater and on the expression of c-fos in the caudal trigeminal nucleus in an experimental migraine model. J. Neurusci. Res. 48, 449-464 (1997).
138. Knyihar-Csillik E, Toldi J, Krisztin-Peva B et al.: Prevention of electrical stimulation-induced increase of c-fos immunoreaction in the caudal trigeminal nucleus by kynurenine combined with probenecid. Neurosci. Lett. 418, 122-126 (2007).
139. Tackling the global burden of stroke. Lancet Neurol. 4, 689 (2005).
140. Saver JL: Time is brain - quantified. Stroke 37, 263-266 (2006).
141. Dirnagl U, Iadecola C, Moskowitz MA: Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci. 22, 391-397 (1999).
142. Furlan AJ, Katzan IL, Caplan LR: Thrombolytic therapy in acute ischemic stroke. Curr. Treat. Options Cardiovasc. Med. 5, 171-180 (2003).
143. Green AR, Ashwood T, Odergren T, Jackson DM: Nitrones as neuroprotective agents in cerebral ischemia, with particular reference to NXY-059. Pharmacol Ther. 100, 195-214 (2003).
144. Hoyte L, Barber PA, Buchan AM, Hill MD: The rise and fall of NMDA antagonists for ischemic stroke. Curr. Mol. Med. 4, 131-136 (2004).
145. Luchowska E, Luchowski P, Sarnowska A, Wielosz M, Turski WA, Urbanska EM: Endogenous level of kynurenic acid and activities of kynurenine aminotransferases following transient global ischemia in the gerbil hippocampus.Pol. J. Pharmacol. 55, 443-447 (2003).
146. Saito Y, Nowak TS Jr, Suyama K et al.: Kynurenine pathway enzymes in brain: responses to ischemic brain injury versus systemic immune activation. J. Neurochem. 61, 2061-2070 (1993).
147. Salvati P, Ukmar G, Dho L et al.: Brain concentrations of kynurenic acid after systemic neuroprotective dose in the gerbil model of global ischemia. Prog Neuropsychopharmacol. Biol. Psychiatry 23, 741-752 (1999).
148. Bari F, Nagy K, Guidetti P, Schwarcz, R, Busija DW, Domoki F: Kynurenic acid attenuates NMDA-induced pial arteriolar dilation in newborn pigs. Brain Res. 1069, 39-46 (2006).
149. Heyes MP, Nowak TS Jr: Delayed increases in regional brain quinolinic acid follow transient ischemia in the gerbil. J. Cereb. Blood Flow Metab. 10, 660-667 (1990).
150. Barber PA, Auer RN, Buchan AM, Sutherland GR: Understanding and managing ischemic stroke. Can. J. Physiol. Pharmacol. 79, 283-296 (2001).
151. Cheng YD, Al-Khoury L, Zivin JA: Neuroprotection for ischemic stroke: two decades of success and failure. NeuroRx 1, 36-45 (2004).
152. Hoyte L, Kaur J, Buchan AM: Lost in translation: taking neuroprotection from animal models to clinical trials. Exp. Neurol. 188, 200-204 (2004).
153. Dronne MA, Grenier E, Chapuisat G, Hommel M, Boissel JP: A modelling approach to explore some hypotheses of the failure of neuroprotective trials in ischemic stroke patients. Prog. Biophys. Mol Biol. DOI: 10.1016/j.pbiomolbio. 2007.10.001 (2007) (Epub ahead of print).
154. Davis M, Mendelow AD, Perry RH, Chambers IR, James OF: Experimental stroke and neuroprotection in the aging rat brain. Stroke 26, 1072-1078 (1995).
155. Schaller BJ: Influence of age on stroke and preconditioning-induced ischemic tolerance in the brain. Exp. Neurol. 205, 9-19 (2007).
156. Obrenovitch TP, Urenjak J: Altered glutamatergic transmission in neurological disorders: from high extracellular glutamate to excessive synaptic efficacy. Prog. Neurobiol. 51, 39-87 (1997).
157. Anderson CM, Swanson RA: Astrocyte glutamate transport: review of properties, regulation, and physiological functions. Glia 32, 1-14 (2000).
158. Yu AC, Schousboe A, Hertz L: Metabolic fate of 14C-labeled glutamate in astrocytes in primary cultures. J. Neurochem. 39, 954-960 (1982).
159. Harris EW: Subtypes of glutamate receptors: pharmacological classification. In: CNS Neurotransmitter and Modulators: Glutamate. Stone TW (Ed.). CRC Press, FL, USA 95-126 (1995).
160. Ascher P, Nowak I: The role of divalent cations in the N-methyl-D-aspartate responses of mouse central neurones in culture [i J. Physiol. 399, 247-266 (1988).
161. Konig N, Poluch S, Estabel J, Durand M, Drian MJ, Exbrayat JM: Synaptic and non-synaptic AMPA receptors permeable to calcium. Jpn J. Pharmacol. 86, 1-17 (2001).
162. 2+ after exposure to glutamate receptor agonist. Exp. Brain Res. 73, 447-458 (1988).
163. Swartz KJ, During MJ, Freese A, Beal MF: Cerebral synthesis and release of kynurenic acid: an endogenous antagonist of excitatory amino acid receptors. J. Neurosci. 10, 2965-2973 (1990).
164. Prescott C, Weeks AM, Staley KJ, Partin KM: Kynurenic acid has a dual action on AMPA receptor responses. Neurosci. Lett. 402, 108-112 (2006).
165. Foster AC, Vezzani A, French ED, Schwarcz R: Kynurenic acid blocks neurotoxicity and seizures induced in rats by the related brain metabolite quinolinic acid. Neurosci. Lett. 48, 273-278 (1984).
166. Hicks RR, Smith DH, Gennarelli TA, McIntosh T: Kynurenate is neuroprotective following experimental brain injury in the rat. Brain Res. 655, 91-96 (1994).
167. Gigler G, Szenasi G, Simo, A et al.: Neuroprotective effect of L-kynurenine sulfate administered before focal cerebral ischemia in mice and global cerebral ischemia in gerbils. Eur. J. Pharmacol. 564, 116-122 (2007).
168. Vecsei L, Beal MF: Intracerebroventricular injection of kynurenic acid, but not kynurenine, induces ataxia and stereotyped behavior in rats. Brain Res. Bull. 25, 623-627 (1990).
169. Nemeth H, Robotka H, Kis Z et al.: Kynurenine administered together with probenecid markedly inhibits pentylenetetrazol-induced seizures. An electrophysiological and behavioural study. Neuropharmacology 47, 916-925 (2004).
170. Vecsei L, Miller J, MacGarvey U, Beal MF: Kynurenine and probenecid inhibit pentylenetetrazol- and NMDLA-induced seizures and increase kynurenic acid concentrations in the brain. Brain Res. Bull. 28, 233-238 (1992).
171. Wu HQ, Lee SC, Schwarcz R: Systemic administration of 4-chlorokynurenine prevents quinolinate neurotoxicity in the rat hippocampus. Eur J. Pharmacol. 390, 267-274 (2000).
172. Wu HQ, Lee SC, Scharfman HE, Schwarcz R: L-4-chlorokynurenine attenuates kainate-induced seizures and lesions in the rat. Exp Neurol. 177, 222-232 (2002).
173. Kemp JA, Foster AC, Leeson PD et al.: 7-Chlorokynurenic acid is a selective antagonist at the glycine modulatory site of the N-methyl-D-aspartate receptor complex. Proc. Natl Acad. Sci. USA 85, 6547-6550 (1988).
174. Moroni F, Alesiani M, Galb A et al.: Thiokynurenates: a new group of antagonists of the glycine modulatory site of the NMDA receptor. Eur. J. Pharmacol. 199, 227-232 (1991).
175. Moroni F, Alesiani M, Facci L et al.: Thiokynurenates prevent excitotoxic neuronal death in vitro and in vivo by acting as glycine antagonists and as inhibitors of lipid peroxidation. Eur. J. Pharmacol. 218, 145-151 (1992).
176. Battaglia G, La Russa M, Bruno V et al.: Systemically administered D-glucose conjugates of 7-chlorokynurenic acid are centrally available and exert anticonvulsant activity in rodents. Brain Res. 860, 149-156 (2000).
177. Bonina FP, Arenare L, Ippolito R et al.: Synthesis, pharmacokinetics and anticonvulsant activity of 7-chlorokynurenic acid prodrugs. Int. J. Pharm. 202, 79-88 (2000).
178. Robotka H, Nemeth H, Somlai C, Vecsei L, Toldi J: Systemically administered glucosamine-kynurenic acid, but not pure kynurenic acid, is effective in decreasing the evoked activity in area CA1 of the rat hippocampus. Eur. J. Pharmacol. 513, 75-80 (2005).
179. Fuvesi J, Somlai C, Nemeth H et al.: Comparative study on the effects of kynurenic acid and glucosamine-kynurenic acid. Pharmacol. Biochem. Behav. 77, 95-102 (2004).
180. Eastman CL, Guilarte TR: Cytotoxicity of 3-hydroxykynurenine in a neuronal hybrid cell line. Brain Res. 495, 225-231 (1989).
181. Connick JH, Heywood GC, Sills GJ, Thompson GG, Brodie MJ, Stone TW: Nicotinylalanine increases cerebral kynurenic acid content and has anticonvulsant activity. Gen. Pharmacol. 23, 235-239 (1992).
182. Russi P, Alesiani M, Lombardi G, Davolio P, Pellicciari F, Moroni F: Nicotinylalanine increases the formation of kynurenic acid in the brain and antagonizes convulsions. J. Neurochem. 59, 2076-2080 (1992).
183. Harris CA, Miranda AF, Tanguay JJ, Boegman RJ, Beninger RJ, Jhamandas K: Modulation of striatal quinolinate neurotoxicity by elevation of endogenous brain kynurenic acid. Br. J. Pharmacol. 124, 391-399 (1998).
184. Miranda AF, Sutton MA, Beninger RJ, Jhamandas K, Boegman RJ: Quinolinic acid lesion of the nigrostriatal pathway: effect on turning behaviour and protection by elevation of endogenous kynurenic acid in Rattus norvegicus. Neurosci. Lett. 262, 81-84. (1999).
185. Moroni F, Russi P, Gallo-Mezo MA, Moneti G, Pellicciari R: Modulation of quinolinic and kynurenic acid content in the rat brain: effects of endotoxins and nicotinylalanine. J. Neurochem. 57, 1630-1635 (1991).
186. Carpenedo R, Chiarugi A, Russi P et al.: Inhibitors of kynurenine hydroxylase and kynureninase increase cerebral formation of kynurenate and have sedative and anticonvulsant activities. Neuroscience 61, 237-243 (1994).
187. Pellicciari R, Natalini B, Costantino G et al.: Modulation of the
188. Speciale C, Wu HQ, Cini M, Marconi M, Varasi M, Schwarcz R. (R,S)-3,4-dichlorobenzoylalanine (FCE 28833A) causes a large and persistent increase in brain kynurenic acid levels in rats. Eur. J. Pharmacol. 315, 263-267 (1996).
189. Rover S, Cesura AM, Huguenin P, Kettler R, Szente A: Synthesis and biochemical evaluation of N-(4-phenylthiazol-2-yl)benzenesulfonamides as high-affinity inhibitors of kynurenine 3-hydroxylase. J. Med. Chem. 40, 4378-4385 (1997).
190. Cozzi A, Carpenedo R, Moroni F: Kynurenine hydroxylase inhibitors reduce ischemic brain damage: studies with (m-nitrobenzoyl)-alanine (mNBA) and 3,4-dimethoxy-[-N-4-(nitrophenyl)thiazol-2yl]- benzenesulfonamide (Ro 61-8048) in models of focal or global brain ischemia. J. Cereb. Blood Flow Metab. 19, 771-777 (1999).
191. Carpenedo R, Meli E, Peruginelli F, Pellegrini-Giampietro DE, Moroni F: Kynurenine 3-mono-oxygenase inhibitors attenuate post-ischemic neuronal death in organotypic hippocampal slice cultures. J. Neurochem. 82, 1465-1471 (2002).
192. Chiarugi A, Moroni F: Quinolinic acid formation in immune-activated mice: studies with (m-nitrobenzoyl)-alanine (mNBA) and 3,4-dimethoxy-[-N-4-(-3-nitrophenyl)thiazol-2yl]-benzenesul fonamide (Ro 61-8048), two potent and selective inhibitors of kynurenine hydroxylase. Neuropharmacology 38, 1225-1233 (1999).
193. Moroni F, Cozzi A. Carpendo R, Cipriani G, Veneroni O, Izzo E: Kynurenine 3-mono-oxygenase inhibitors reduce glutamate concentration in the extracellular spaces of the basal ganglia but not in those of the cortex or hippocampus. Neuropharmacology 48, 788-795 (2005).
194. Ceresoli-Borroni G, Guidetti P, Amori L, Pellicciari R, Schwarcz R: Perinatal kynurenine 3-hydroxylase inhibition in rodents: pathophysiological implications. J. Neurosci. Res. 85, 845-854 (2007).
195. Kishore GM: Mechanism-based inactivation of bacterial kynureninase by β-substituted amino acids. J. Biol. Chem 259, 10669-10674 (1984).
196. Drysdale MJ, Reinhard JF: S-aryl cysteine S,S-dioxides as inhibitors of mammalian kynureninase. Bioorg. Med. Chem. Lett. 8, 133-138 (1998).
197. Fitzgerald DH, Muirhead KM, Botting NP: A comparative study on the inhibition of human and bacterial kynureninase by novel bicyclic kynurenine analogues. Bioorg. Med. Chem. 9, 983-989 (2001).
198. Walsh HA, Leslie PL, O'Shea KC, Botting NP: 2-amino-4-[3′-hydroxyphenyl]-4-hydroxybutanoic acid; a potent inhibitor of rat and recombinant human kynureninase. Bioorg. Med. Chem. Lett. 12, 361-363 (2002).
199. Walsh HA, O'Shea KC, Boning NP: Comparative inhibition by substrate analogues 3-methoxy- and 3-hydroxydesamino-kynurenine and an improved 3 step purification of recombinant human kynureninase. BMC Biochem. 4, 13 (2003).
200. Heyes M, Hutto B, Markey S: 4-chloro-3-hydroxyanthranilate inhibits brain 3-hydroxyanthranilate oxygenase. Neurchem. Int. 13, 405-408 (1988).
201. Saito K, Chen CY, Masana M, Crowley JS, Markey SP, Heyes MP: 4-chloro-3-hydroxyanthranilate, 6-chlorotryptophan and norharmane attenuate quinolinic acid formation by interferon-γ-stimulated monocytes (THP-1 cells). Biochem. J. 291(Pt 1), 11-14 (1993).
202. Walsh JI, Todd WP Carpenter BK, Schwartz R: 4-halo-3-hydroxyanthranilic acids: potent competitive inhibitors of 3-hydroxy-anthranilic acid oxygenase in vitro. Biochem. Pharmacoll 42, 985-990 (1991).
203. Walsh JL, Todd WP, Carpenter BK, Schwarcz R: 4-halo-3-hydroxyanthranilates are potent inhibitors of 3-hydroxyanthranilate oxygenase in the rat brain in vitro and in vivo. Adv. Exp. Med. Biol. 294, 579-582 (1991).
204. Colabroy KL, Zhai H, Li T et al.: The mechanism of inactivation of 3-hydroxyanthranilate-3,4-dioxygenase by 4-chloro-3-hydroxyanthranilate. Biochemistry 44, 7623-7631 (2005).
205. Chiarugi A, Moroni F: Effects of mitochondria and o-methoxybenzoylalanine on 3-hydroxyanthranilicc acid dioxygenase activity and quinolinic acid synthesis. J. Neurochem. 72, 1125-1132 (1999).
206. Linnderberg M, Hellberg S, Björk S et al.: Synthesis and QSAR of substituted 3-hydroxyanthranilic acid derivatives as inhibitors of 3-hydroxyanthranilic acid dioxygenase (3-HAO). Eur. J. Med. Chem. 34, 729-744 (1999).
207. Luthman J, Vanerman E, Fredriksson G, Fornstedt-Wallin B: Regulation of quinolinic acid in the normal rat brain by kynurenine pathway precursors. Adv. Exp. Med. Biol. 398, 229-239 (1996).
208. Lathman J, Radesater AC, Oberg C: Effects of the 3-hydroxyanthranilic acid analogue NCR-631 on anoxia-, IL-1 β- and LPS-induced hippocampal pyramidal cell loss in vitro. Amino Acids 14, 263-269 (1998).
209. Fornstedt-Willin B, Lundstrom J, Fredriksson G, Schwartz R, Luthman J: 3-Hydroxyanthranilic acid accumulation following-administration of the 3-hydroxyanthranilic acid 3,4-dioxygensae inhibitor NCR-631. Eur. J. Phamacol. 386, 15-24 (1999).
210. Platten M, Ho PP, Youssef S et al.: Treatment of autoimmune neuroinflammation with a synthetic tryptophan metabolite. Science 310, 850-855 (2005).
211. Luchowski P, Kocki T, Urbanska EM: N(G)-nitro-L-arginine and its methyl ester inhibit brain synthesis of kynurenic acid possibly via nitric oxide-independent mechanism. Pol. J. Pharmacol. 53, 597-604 (2001).
212. Battaglia G, Rassoulpour A, Wu HQ et al.: Some metabotropic glutamate receptor ligands reduce kynurenate synthesis in rats by intracellular inhibition of kynurenine aminotransferase II. J. Neurochem. 75, 2051-2060 (2000).
213. Stone TW: Inhibitors of the kynurenine pathway. Eur. J. Med. Chem. 35, 179-186 (2000).
214. Schwartz R, Pellicciari R: Manipulation of brain kynurenines: glial targets, neuronal effects, and clinical opportunities. J. Pharmacol. Exp. Ther. 303, 1-10 (2002).